

Nonclinical studies addressing the mechanism of action

Seminars in Oncology

26, 60-70

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anticancer drug targets: growth factors and growth factor signaling. <i>Journal of Clinical Investigation</i> , 2000, 105, 9-13.	3.9	125
2	Genetic changes in solid tumors. , 2000, 18, 358-370.		6
3	Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. <i>Oncogene</i> , 2000, 19, 6102-6114.	2.6	518
4	The EGF receptor family as targets for cancer therapy. <i>Oncogene</i> , 2000, 19, 6550-6565.	2.6	1,251
5	Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. <i>EMBO Journal</i> , 2000, 19, 4632-4643.	3.5	126
6	Evaluation of Endocrine Neoplasms Using Fine Needle Aspiration Biopsy. <i>Endocrine Pathology</i> , 2000, 11, 301-314.	5.2	1
7	Sustained Down-regulation of the Epidermal Growth Factor Receptor by Decorin. <i>Journal of Biological Chemistry</i> , 2000, 275, 32879-32887.	1.6	195
8	An Anti-oncogenic Role for Decorin. <i>Journal of Biological Chemistry</i> , 2000, 275, 35153-35161.	1.6	183
9	Mechanism-Based Target Identification and Drug Discovery in Cancer Research. <i>Science</i> , 2000, 287, 1969-1973.	6.0	442
10	Nursing management considerations with trastuzumab (herceptin). <i>Seminars in Oncology Nursing</i> , 2000, 16, 23-28.	0.7	2
11	Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. <i>Breast Cancer Research</i> , 2000, 2, 176-83.	2.2	127
12	Biological Therapy of Breast Cancer. <i>BioDrugs</i> , 2000, 14, 221-246.	2.2	8
13	Treatment and Outcomes for Elderly Patients with Small Cell Lung Cancer. <i>Drugs and Aging</i> , 2000, 17, 229-247.	1.3	28
14	Taxol biosynthesis: Molecular cloning of a benzoyl- CoA:taxane 2alpha -O-benzoyltransferase cDNA from <i>Taxus</i> and functional expression in <i>Escherichia coli</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 13591-13596.	3.3	147
15	Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. <i>Gastroenterology</i> , 2001, 120, 1713-1719.	0.6	179
16	2000 Highlights From: 23rd Annual San Antonio Breast Cancer Symposium; San Antonio, Texas December 6-9, 2000. <i>Clinical Breast Cancer</i> , 2001, 1, 264-269.	1.1	0
17	HER2/neu as a Predictive Factor in Breast Cancer. <i>Clinical Breast Cancer</i> , 2001, 2, 129-135.	1.1	58
18	New Horizons in Treating Metastatic Disease. <i>Clinical Breast Cancer</i> , 2001, 1, 276-287.	1.1	18

#	ARTICLE	IF	CITATIONS
19	THE PERIPHERAL BLOOD LEUKOCYTE PHENOTYPE IN PATIENTS WITH BREAST CANCER: EFFECT OF DOXORUBICIN/PACLITAXEL COMBINATION CHEMOTHERAPY. <i>Immunopharmacology and Immunotoxicology</i> , 2001, 23, 163-173.	1.1	30
20	Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?. <i>Breast Cancer Research</i> , 2001, 3, 86.	2.2	34
21	Biology of HER2 and Its Importance in Breast Cancer. <i>Oncology</i> , 2001, 61, 1-13.	0.9	551
22	Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. <i>Cancer Letters</i> , 2001, 165, 147-153.	3.2	79
23	First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer. <i>European Journal of Cancer</i> , 2001, 37, 25-29.	1.3	154
24	Mechanism of action of anti-HER2 monoclonal antibodies. <i>Annals of Oncology</i> , 2001, 12, S35-S41.	0.6	179
25	Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2001, 61, 3-13.	0.9	137
26	Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. <i>Cytometry</i> , 2001, 44, 338-348.	1.8	46
27	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells. <i>European Journal of Immunology</i> , 2001, 31, 3016-3025.	1.6	141
28	Degradation Signals in ErbB-2 Dictate Proteasomal Processing and Immunogenicity and Resist Protection by cis Glycine-Alanine Repeat. <i>Cellular Immunology</i> , 2001, 212, 138-149.	1.4	15
29	Trastuzumab: Designer Drug or Fashionable Fad?. <i>Clinical Oncology</i> , 2001, 13, 427-433.	0.6	1
30	Molecular targets for breast cancer therapy and prevention. <i>Nature Medicine</i> , 2001, 7, 548-552.	15.2	263
31	Untangling the ErbB signalling network. <i>Nature Reviews Molecular Cell Biology</i> , 2001, 2, 127-137.	16.1	5,977
32	Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. <i>Journal of Immunological Methods</i> , 2001, 248, 103-111.	0.6	71
33	Functional Analysis of Csk and CHK Kinases in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 33711-33720.	1.6	36
34	Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design. <i>Journal of Immunology</i> , 2001, 166, 5271-5278.	0.4	73
35	Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody. <i>Journal of Immunology</i> , 2001, 167, 3201-3206.	0.4	64
36	Phase I and II clinical trials of trastuzumab. <i>Annals of Oncology</i> , 2001, 12, S49-S55.	0.6	68

#	ARTICLE	IF	CITATIONS
37	Breast Cancer in the 21st Century: Neu Opportunities and Neu Challenges. <i>Modern Pathology</i> , 2001, 14, 213-218.	2.9	53
38	Monoclonal antibody therapy. <i>Advances in Protein Chemistry</i> , 2001, 56, 369-421.	4.4	11
39	Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity. <i>Journal of Immunology</i> , 2002, 168, 3275-3282.	0.4	24
40	Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8880-8885.	3.3	418
41	Recent Advances in the Systemic Management of Metastatic Breast Cancer. <i>Journal of Pharmacy Practice</i> , 2002, 15, 52-61.	0.5	2
42	Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. <i>Annals of Oncology</i> , 2002, 13, 8-9.	0.6	32
43	Cellular immunity to the Her-2/neu protooncogene. <i>Advances in Cancer Research</i> , 2002, 85, 101-144.	1.9	72
44	Individual-based simulation of the clustering behaviour of epidermal growth factor receptors.. , 2002, , .		1
45	Resistance to Trastuzumab: A Necessary Evil or a Temporary Challenge?. <i>Clinical Breast Cancer</i> , 2002, 3, 247-257.	1.1	60
46	The role of the ubiquitination-proteasome pathway in breast cancer: Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. <i>Breast Cancer Research</i> , 2002, 5, 8-15.	2.2	45
47	Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. <i>Journal of Cell Science</i> , 2002, 115, 4251-4262.	1.2	167
48	Oxaliplatin: A Review of Evolving Concepts. <i>Cancer Investigation</i> , 2002, 20, 246-263.	0.6	58
49	Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. <i>Lung Cancer</i> , 2002, 37, 17-27.	0.9	27
50	Trastuzumab in the treatment of nonâ€“small cell lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 59-65.	0.8	37
51	Molecular targets as therapeutic strategies in the management of breast cancer. <i>Seminars in Radiation Oncology</i> , 2002, 12, 341-351.	1.0	9
52	Signaling revealed by mapping molecular interactions. <i>Clinical and Applied Immunology Reviews</i> , 2002, 2, 169-186.	0.4	12
53	HER2/neu in the management of invasive breast cancer. <i>Journal of the American College of Surgeons</i> , 2002, 194, 488-501.	0.2	39
54	Trastuzumab-associated cardiotoxicity. <i>Cancer</i> , 2002, 95, 1592-1600.	2.0	316

#	ARTICLE	IF	CITATIONS
55	Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. <i>British Journal of Surgery</i> , 2002, 89, 262-271.	0.1	49
56	Landing of immune receptors and signal proteins on lipid rafts: a safe way to be spatio-temporally coordinated?. <i>Immunology Letters</i> , 2002, 82, 3-15.	1.1	32
57	Enhanced Anti-tumor Effect of Trastuzumab in Combination with Cisplatin. <i>Japanese Journal of Cancer Research</i> , 2002, 93, 574-581.	1.7	19
58	Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins. <i>Cancer Gene Therapy</i> , 2002, 9, 884-896.	2.2	15
59	Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells. <i>Oncogene</i> , 2002, 21, 5224-5232.	2.6	65
60	c-erbB-2 is not a major factor in the development of colorectal cancer. <i>British Journal of Cancer</i> , 2002, 86, 568-573.	2.9	62
61	Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: A case report. <i>Breast Cancer</i> , 2003, 10, 170-174.	1.3	5
62	Molecular pathology of tumor metastasis III. <i>Pathology and Oncology Research</i> , 2003, 9, 49-72.	0.9	10
63	HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?. <i>Gynecologic Oncology</i> , 2003, 88, 263-265.	0.6	40
64	Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. <i>Cancer</i> , 2003, 98, 1377-1385.	2.0	104
65	Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling. <i>International Journal of Cancer</i> , 2003, 104, 303-309.	2.3	15
66	Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. <i>International Journal of Cancer</i> , 2003, 107, 976-983.	2.3	49
67	Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. <i>Nature</i> , 2003, 421, 756-760.	18.7	1,363
68	Biologic and therapeutic role of HER2 in cancer. <i>Oncogene</i> , 2003, 22, 6570-6578.	2.6	379
69	HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. <i>Oncogene</i> , 2003, 22, 6739-6747.	2.6	33
70	Labeling anti-HER2/neu Monoclonal Antibodies with ¹¹¹ In and ⁹⁰ Y Using a Bifunctional DTPA Chelating Agent. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 355-363.	0.7	42
71	Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. <i>Digestive and Liver Disease</i> , 2003, 35, 332-338.	0.4	60
72	The Anti-HER2 Monoclonal Antibody Pertuzumab May Be Effective in Androgen-Independent Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2003, 2, 143-145.	2.1	5

#	ARTICLE	IF	CITATIONS
73	An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. <i>Molecular Cell</i> , 2003, 12, 541-552.	4.5	774
74	The ErbB receptors and their role in cancer progression. , 2003, , 103-114.		2
75	Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. <i>Journal of Leukocyte Biology</i> , 2003, 74, 593-601.	1.5	17
76	Cell-Type Specific Targeting and Gene Expression Using a Variant of Polyoma VP1 Virus-Like Particles. <i>Biological Chemistry</i> , 2003, 384, 247-55.	1.2	27
77	Design, Construction, and In Vitro Analyses of Multivalent Antibodies. <i>Journal of Immunology</i> , 2003, 170, 4854-4861.	0.4	57
78	The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition. <i>Journal of Biological Chemistry</i> , 2003, 278, 23441-23450.	1.6	132
79	Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1118-1127.	3.0	89
80	A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses. <i>Journal of Immunology</i> , 2003, 170, 4242-4253.	0.4	70
81	HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice. <i>Journal of Immunology</i> , 2003, 171, 2161-2169.	0.4	97
82	Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer: what can be expected and why?. <i>Annals of Oncology</i> , 2003, 14, 1697-1704.	0.6	32
83	Trastuzumab for the Treatment of Non-Small-Cell Lung Cancer. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1904-1908.	0.9	6
84	Phase 1 Study of Paclitaxel Administered Twice Weekly to Children With Refractory Solid Tumors: A Pediatric Oncology Group Study. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 539-542.	0.3	23
86	Mechanism of action of erbB tyrosine kinase inhibitors. , 2003, , 137-145.		1
87	Generation of DOTA-Conjugated Antibody Fragments for Radioimmunoimaging. <i>Methods in Enzymology</i> , 2004, 386, 262-275.	0.4	8
88	Molecular biological design of novel antineoplastic therapies. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 577-607.	1.9	6
89	Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes. <i>Clinical Cancer Research</i> , 2004, 10, 2538-2544.	3.2	56
90	A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab ²) ₂ Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies. <i>Clinical Cancer Research</i> , 2004, 10, 3542-3551.	3.2	83
91	Caspase-8-Dependent HER-2 Cleavage in Response to Tumor Necrosis Factor α Stimulation Is Counteracted by Nuclear Factor κ B through c-FLIP-L Expression. <i>Cancer Research</i> , 2004, 64, 2684-2691.	0.4	37

#	ARTICLE	IF	CITATIONS
92	P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells. <i>Cancer Research</i> , 2004, 64, 3981-3986.	0.4	283
93	Structure and Function of the Epidermal Growth Factor (EGF) Family of Receptors. <i>Advances in Protein Chemistry</i> , 2004, 68, 1-27.	4.4	70
94	Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin. <i>Molecular Biology of the Cell</i> , 2004, 15, 5268-5282.	0.9	436
95	Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction. <i>Clinical Cancer Research</i> , 2004, 10, 2512-2524.	3.2	77
96	Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase. <i>Cancer Research</i> , 2004, 64, 3958-3965.	0.4	570
97	Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 13756-13761.	3.3	174
98	Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin). <i>Clinical Cancer Research</i> , 2004, 10, 1409-1420.	3.2	70
99	Therapeutic HER2/Neu DNA Vaccine Inhibits Mouse Tumor Naturally Overexpressing Endogenous Neu. <i>Molecular Therapy</i> , 2004, 10, 290-301.	3.7	51
100	Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas. <i>British Journal of Cancer</i> , 2004, 91, 1195-1199.	2.9	51
101	Trastuzumab-based combination therapy for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 81-96.	0.9	43
102	HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice. <i>Clinical Cancer Research</i> , 2004, 10, 2499-2511.	3.2	108
103	Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast. <i>Histopathology</i> , 2004, 45, 142-147.	1.6	11
104	A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. <i>British Journal of Cancer</i> , 2004, 91, 1200-1204.	2.9	41
105	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. <i>Cancer Cell</i> , 2004, 6, 117-127.	7.7	1,693
106	Successful targeting of ErbB2 receptors is PTEN the key?. <i>Cancer Cell</i> , 2004, 6, 103-104.	7.7	197
107	Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere). <i>Breast Cancer Research and Treatment</i> , 2004, 84, 183-195.	1.1	71
108	Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma. <i>Breast Cancer Research and Treatment</i> , 2004, 86, 125-137.	1.1	47
109	Generation and Production of Engineered Antibodies. <i>Molecular Biotechnology</i> , 2004, 26, 39-60.	1.3	57

#	ARTICLE	IF	CITATIONS
110	Targeting multiple signal transduction pathways through inhibition of Hsp90. <i>Journal of Molecular Medicine</i> , 2004, 82, 488-99.	1.7	325
111	Immunobiology of HER-2/ neu oncoprotein and its potential application in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 166-175.	2.0	60
112	Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. <i>International Journal of Cancer</i> , 2004, 108, 71-77.	2.3	138
113	CD4+T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. <i>International Journal of Cancer</i> , 2004, 109, 259-264.	2.3	46
114	Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. <i>International Journal of Cancer</i> , 2004, 112, 492-501.	2.3	46
115	Signal transduction and oncogenesis by ErbB/HER receptors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 903-913.	0.4	333
116	Mechanism by Which Orally Administered β -1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models. <i>Journal of Immunology</i> , 2004, 173, 797-806.	0.4	419
117	Phase II Study of Trastuzumab plus Gemcitabine in Chemotherapy-Pretreated Patients with Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 142-147.	1.1	117
118	Cetuximab as a Single Agent or in Combination with Chemotherapy in Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 6, S80-S84.	1.1	13
119	Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. <i>Cancer Letters</i> , 2004, 214, 215-224.	3.2	63
120	Complement function in mAb-mediated cancer immunotherapy. <i>Trends in Immunology</i> , 2004, 25, 158-164.	2.9	248
121	Targeted therapy for malignant gliomas. <i>Journal of Clinical Neuroscience</i> , 2004, 11, 807-818.	0.8	25
122	Comparison of HER2 mRNA Amplification with Immunohistochemistry in Human Breast Cancer Using Laser Assisted Microdissection Technique. <i>Acta Histochemica Et Cytochemica</i> , 2004, 37, 73-79.	0.8	11
123	Cytometry of Fluorescence Resonance Energy Transfer. <i>Methods in Cell Biology</i> , 2004, 75, 105-152.	0.5	26
124	Mechanisms of Trastuzumab Resistance and Their Clinical Implications. <i>Annals of the New York Academy of Sciences</i> , 2005, 1059, 70-75.	1.8	68
125	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin [®]) in breast cancer cells with Her-2/neu oncogene amplification. <i>Annals of Oncology</i> , 2005, 16, 359-371.	0.6	197
126	Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. <i>British Journal of Cancer</i> , 2005, 92, 342-349.	2.9	128
127	ERBB receptors and cancer: the complexity of targeted inhibitors. <i>Nature Reviews Cancer</i> , 2005, 5, 341-354.	12.8	2,930

#	ARTICLE	IF	CITATIONS
128	Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. <i>Oncogene</i> , 2005, 24, 6657-6666.	2.6	27
129	Anti-HER3 MAb inhibits HER3-mediated signaling in breast cancer cell lines resistant to anti-HER2 antibodies. <i>International Journal of Cancer</i> , 2005, 115, 519-527.	2.3	48
130	Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. <i>International Journal of Cancer</i> , 2005, 116, 359-367.	2.3	130
131	Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. <i>International Journal of Cancer</i> , 2005, 116, 710-719.	2.3	71
132	Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: Local stimulation using magnetic microspheres as assessed by quantitative digital microscopy. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2005, 67A, 161-171.	1.1	19
133	Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2135-2146.	1.6	560
134	Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 468-476.	2.0	30
135	Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 203-211.	0.4	43
136	Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. <i>Clinical and Translational Oncology</i> , 2005, 7, 99-100.	1.2	8
137	Strategies and methodologies for identifying molecular targets in sarcomas and other tumors. <i>Current Treatment Options in Oncology</i> , 2005, 6, 487-497.	1.3	5
138	Optimizing the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, S9-S15.	1.1	64
139	Endocrine therapy – current benefits and limitations. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 3-10.	1.1	223
140	Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 487-499.	2.7	186
141	Designing antibodies for oncology. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 585-598.	2.7	16
142	Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 956-967.	1.9	37
143	In Vitro and In Vivo Characterization of a Novel Antibody-Like Single-Chain TCR Human IgG1 Fusion Protein. <i>Journal of Immunology</i> , 2005, 174, 4381-4388.	0.4	29
144	Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel. <i>Clinical Cancer Research</i> , 2005, 11, 1983-1989.	3.2	128
145	Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 938-947.	1.9	11

#	ARTICLE	IF	CITATIONS
146	Inhibition of Adhesion, Invasion, and Metastasis by Antibodies Targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). <i>Cancer Research</i> , 2005, 65, 8809-8817.	0.4	184
147	In vitro cytotoxicity of carcinoma cells with ¹¹¹ In-labeled antibodies to HER-2. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 927-937.	1.9	18
148	Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2005, 92, 1253-1260.	2.9	106
149	Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging. <i>Cancer Research</i> , 2005, 65, 5907-5916.	0.4	158
150	A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2. <i>Journal of Biological Chemistry</i> , 2005, 280, 4656-4662.	1.6	46
151	Hsp90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Prevents Synovial Sarcoma Proliferation via Apoptosis in In vitro Models. <i>Clinical Cancer Research</i> , 2005, 11, 5631-5638.	3.2	48
152	Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity against Esophageal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 4898-4904.	3.2	79
153	Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling. <i>Journal of Biological Chemistry</i> , 2005, 280, 2092-2104.	1.6	60
154	Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. <i>Experimental Cell Research</i> , 2005, 304, 604-619.	1.2	155
155	HER2-Mediated Internalization of a Targeted Prodrug Cytotoxic Conjugate Is Dependent on the Valency of the Targeting Ligand. <i>DNA and Cell Biology</i> , 2005, 24, 351-358.	0.9	28
156	Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu – a new method of epitope definition. <i>Molecular Immunology</i> , 2005, 42, 1121-1124.	1.0	32
157	SRL172 (killed <i>Mycobacterium vaccae</i>) may augment the efficacy of trastuzumab in metastatic breast cancer patients. <i>Medical Hypotheses</i> , 2005, 64, 248-251.	0.8	3
158	Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. <i>Medical Hypotheses</i> , 2005, 64, 997-1001.	0.8	72
159	Antitumor activity of HER-2 inhibitors. <i>Cancer Letters</i> , 2005, 227, 9-23.	3.2	82
160	Associations of ErbB2, β 1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. <i>Cancer Letters</i> , 2005, 227, 201-212.	3.2	42
161	HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: An unexpected effect on TRAIL-induced apoptosis. <i>FEBS Letters</i> , 2005, 579, 4149-4158.	1.3	37
162	The antitumor immune response in HER-2 positive, metastatic breast cancer patients. <i>Journal of Translational Medicine</i> , 2005, 3, 13.	1.8	9
163	HER2 therapy: Molecular mechanisms of trastuzumab resistance. <i>Breast Cancer Research</i> , 2006, 8, 215.	2.2	357

#	ARTICLE	IF	CITATIONS
164	Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents, 2006, 16, 147-164.	2.4	3
165	Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγR1IIa. Clinical Cancer Research, 2006, 12, 2879-2887.	3.2	198
166	Tumor Cell Purging by Ex Vivo Expansion of Hemopoietic Stem Cells from Breast Cancer Patients Combined with Targeting ErbB Receptors. Biology of Blood and Marrow Transplantation, 2006, 12, 68-74.	2.0	5
167	Dendritic Cell Immunotherapy for the Treatment of Neoplastic Disease. Biology of Blood and Marrow Transplantation, 2006, 12, 113-125.	2.0	27
168	Sequestering ErbB2 in endoplasmic reticulum by its autoinhibitor from translocation to cell surface: An autoinhibition mechanism of ErbB2 expression. Biochemical and Biophysical Research Communications, 2006, 342, 19-27.	1.0	13
169	Herceptin: mechanisms of action and resistance. Cancer Letters, 2006, 232, 123-138.	3.2	407
170	Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. European Journal of Cancer, 2006, 42, 186-192.	1.3	25
171	High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Molecular Immunology, 2006, 43, 1183-1193.	1.0	137
172	Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents. Update on Cancer Therapeutics, 2006, 1, 159-173.	0.9	5
173	HER2 Testing in Breast Cancer: Opportunities and Challenges. Breast Care, 2006, 1, 69-76.	0.8	4
174	Defective Antitumor Function of Monocyte-Derived Macrophages from Epithelial Ovarian Cancer Patients. Clinical Cancer Research, 2006, 12, 1515-1524.	3.2	81
175	Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer. Annals of the New York Academy of Sciences, 2002, 963, 104-115.	1.8	60
176	Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opinion on Biological Therapy, 2006, 6, 1161-1173.	1.4	158
177	Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer. Annals of Surgical Oncology, 2006, 13, 1085-1098.	0.7	65
178	Increasing of HER2 Membranar Density in Human Glioblastoma U251MG Cell Line Established in a New Nude Mice Model. Journal of Neuro-Oncology, 2006, 76, 249-255.	1.4	11
179	Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunology, Immunotherapy, 2006, 55, 1081-1090.	2.0	45
180	Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunology Letters, 2006, 104, 146-155.	1.1	70
181	Her-2 targeted therapy: Beyond breast cancer and trastuzumab. Current Oncology Reports, 2006, 8, 90-95.	1.8	8

#	ARTICLE	IF	CITATIONS
182	Molecular Predictive Factors in Patients Receiving Trastuzumab-Based Chemotherapy for Metastatic Disease. <i>Clinical Breast Cancer</i> , 2006, 7, 254-261.	1.1	28
183	Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. <i>Medicinal Research Reviews</i> , 2006, 26, 569-594.	5.0	122
184	Developments for the minimally invasive treatment of tumours by targeted magnetic heating. <i>Journal of Physics Condensed Matter</i> , 2006, 18, S2951-S2958.	0.7	21
185	Effects of HER2-Binding Affibody Molecules on Intracellular Signaling Pathways. <i>Tumor Biology</i> , 2006, 27, 201-210.	0.8	21
186	The role of biomarkers in the future of drug development. <i>Expert Opinion on Drug Discovery</i> , 2006, 1, 199-204.	2.5	2
187	Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2â€“positive breast cancer cells in a synergistic manner. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3042-3051.	1.9	58
188	Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 6326-6330.	3.2	114
189	Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 83-131.	1.1	41
190	Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 665-675.	1.9	98
191	Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets. <i>Journal of Immunology</i> , 2006, 177, 120-129.	0.4	109
192	Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent of HER-2/neu Expression. <i>Journal of Immunology</i> , 2006, 176, 7695-7703.	0.4	19
193	Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu. <i>Journal of Immunology</i> , 2007, 178, 7120-7131.	0.4	64
194	New targets for non-small-cell lung cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1423-1437.	1.1	35
195	Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2007, 97, 494-501.	2.9	68
196	Vascular Endothelial Growth Factor Partially Inhibits the Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity of Human Monocytes. <i>Oncology</i> , 2007, 72, 172-180.	0.9	5
197	Emerging drugs for targeted therapy of bladder cancer. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 435-448.	1.0	7
198	Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu. <i>Expert Opinion on Therapeutic Patents</i> , 2007, 17, 83-102.	2.4	10
199	Trastuzumab causes antibody-dependent cellular cytotoxicityâ€“mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2065-2072.	1.9	198

#	ARTICLE	IF	CITATIONS
200	Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2. <i>Journal of Applied Physiology</i> , 2007, 103, 2077-2083.	1.2	35
201	Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion. <i>Cancer Research</i> , 2007, 67, 1842-1852.	0.4	247
202	Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route. <i>Vaccine</i> , 2007, 25, 719-728.	1.7	19
203	Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?. <i>Cancer Treatment Reviews</i> , 2007, 33, 391-406.	3.4	61
204	Molecular targeted therapies in breast cancer: Where are we now?. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1375-1387.	1.2	32
205	Neoadjuvant Therapy for HER-2/neu-Expressing Ductal Carcinoma in Situ Using Type 1 Polarized Dendritic Cell Vaccines. <i>Breast Diseases</i> , 2007, 17, 320-323.	0.0	1
206	EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The Modulator Role of P13K/Akt. <i>Neoplasia</i> , 2007, 9, 614-624.	2.3	42
207	HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. <i>Breast Cancer Research</i> , 2007, 9, .	2.2	51
208	Overview of Resistance to Systemic Therapy in Patients with Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2007, 608, 1-22.	0.8	721
209	Trastuzumab: triumphs and tribulations. <i>Oncogene</i> , 2007, 26, 3637-3643.	2.6	300
210	Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. <i>Nature Reviews Cancer</i> , 2007, 7, 332-344.	12.8	720
211	Primary cutaneous apocrine carcinoma presenting as carcinoma erysipeloides. <i>British Journal of Dermatology</i> , 2007, 158, 071106220718005-???	1.4	12
212	Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SKâ€œ breast cancer cell proliferation. <i>Cell Proliferation</i> , 2007, 40, 488-507.	2.4	72
213	Improving the efficacy of trastuzumab in breast cancer. <i>Cancer Science</i> , 2007, 98, 767-771.	1.7	8
214	Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 49-54.	0.7	94
215	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin,™) in HER2-overexpressing breast cancer cells. <i>BMC Cancer</i> , 2007, 7, 80.	1.1	154
216	Mechanisms for oncogenic activation of the epidermal growth factor receptor. <i>Cellular Signalling</i> , 2007, 19, 2013-2023.	1.7	250
217	Dissecting kinase signaling pathways. <i>Drug Discovery Today</i> , 2007, 12, 717-724.	3.2	18

#	ARTICLE	IF	CITATIONS
218	Exchanging human Fc γ 1 with murine Fc γ 2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 459-468.	2.0	12
219	Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2007, 85, 281-287.	1.4	71
220	Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. <i>Cytotechnology</i> , 2007, 55, 109-114.	0.7	85
221	The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations. <i>Current Treatment Options in Oncology</i> , 2007, 8, 47-60.	1.3	29
222	Recombinant therapeutic monoclonal antibodies: Mechanisms of action in relation to structural and functional duality. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 226-233.	2.0	26
223	Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 241-250.	1.1	38
224	Ultrastructural damage in lung tissues in rats treated with doxorubicin and paclitaxel. <i>Advances in Therapy</i> , 2008, 25, 115-122.	1.3	2
225	Quercetin-induced ubiquitination and down-regulation of Her2/neu. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 585-595.	1.2	65
226	Targeted therapy in the treatment of solid tumors: Practice contradicts theory. <i>Biochemistry (Moscow)</i> , 2008, 73, 605-618.	0.7	35
227	ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a β -secretase inhibitor. <i>Oncogene</i> , 2008, 27, 5019-5032.	2.6	195
228	Unraveling the Biologic and Clinical Complexities of HER2. <i>Clinical Breast Cancer</i> , 2008, 8, 392-401.	1.1	92
229	Aggrin and neuregulin, expanding roles and implications for therapeutics. <i>Biotechnology Advances</i> , 2008, 26, 187-201.	6.0	10
230	Identification of the domain in ErbB2 that restricts ligand-induced degradation. <i>Cellular Signalling</i> , 2008, 20, 779-786.	1.7	14
231	Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation. , 2008, , 251-305.		9
232	Her2-positive breast cancer: Herceptin and beyond. <i>European Journal of Cancer</i> , 2008, 44, 2806-2812.	1.3	168
233	Showering c-MET-dependent cancers with drugs. <i>Current Opinion in Genetics and Development</i> , 2008, 18, 87-96.	1.5	131
234	The Tyrophostin B42 Inhibits Cell Proliferation and HER-2 Autophosphorylation in Cervical Carcinoma Cell Lines. <i>Cancer Investigation</i> , 2008, 26, 136-144.	0.6	8
235	Complement and cellular cytotoxicity in antibody therapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 759-768.	1.4	76

#	ARTICLE	IF	CITATIONS
236	Cardiovascular complications associated with biological therapies for breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1551-1559.	1.4	5
237	HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. <i>Annals of Oncology</i> , 2008, 19, 1523-1529.	0.6	931
238	Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. <i>Cancer Research</i> , 2008, 68, 9280-9290.	0.4	1,422
239	Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 449-454.	1.9	48
240	A Novel Human Her-2/neu Chimeric Molecule Expressed by <i>Listeria monocytogenes</i> Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 924-932.	3.2	53
241	Mimotope vaccination from allergy to cancer. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 493-506.	1.4	87
242	Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise. <i>Integrative Cancer Therapies</i> , 2009, 8, 17-21.	0.8	33
243	Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies. <i>Breast Care</i> , 2009, 4, 46-50.	0.8	0
244	Resistance to Trastuzumab in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7479-7491.	3.2	397
245	Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. <i>Oncologist</i> , 2009, 14, 1-11.	1.9	124
246	Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression. <i>Clinical Breast Cancer</i> , 2009, 9, S50-S57.	1.1	21
247	Ligand-induced ErbB receptor dimerization. <i>Experimental Cell Research</i> , 2009, 315, 638-648.	1.2	185
248	Study of inhibition effect of Herceptin on interaction between Heregulin and ErbB Receptors HER3/HER2 by single-molecule force spectroscopy. <i>Experimental Cell Research</i> , 2009, 315, 2847-2855.	1.2	47
249	Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 95-100.	1.1	12
250	Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 915-930.	2.0	117
251	Engineered therapeutic antibodies with improved effector functions. <i>Cancer Science</i> , 2009, 100, 1566-1572.	1.7	159
252	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. <i>Oncogene</i> , 2009, 28, 803-814.	2.6	385
253	Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. <i>British Journal of Cancer</i> , 2009, 101, 1357-1364.	2.9	27

#	ARTICLE	IF	CITATIONS
254	Human anti-ErbB2 immunoagents – immunoRNases and compact antibodies. FEBS Journal, 2009, 276, 1527-1535.	2.2	19
255	Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2-Positive Breast Cancer. Oncologist, 2009, 14, 1061-1069.	1.9	75
256	Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews, 2009, 35, 685-691.	3.4	52
257	Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomedicine and Pharmacotherapy, 2009, 63, 703-706.	2.5	43
258	Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of ^{117m}Lu -particle-emitting ^{211}At -labeled trastuzumab. Nuclear Medicine and Biology, 2009, 36, 659-669.	0.3	43
259	Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review. American Journal of Emergency Medicine, 2009, 27, 903.e1-903.e3.	0.7	18
260	Targeting Transduction Pathways for Research and Medical Intervention. , 2009, , 735-761.		0
261	Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition. Journal of Drug Targeting, 2009, 17, 474-489.	2.1	23
263	Targeted Inhibition of Kinases in Cancer Therapy. Mount Sinai Journal of Medicine, 2010, 77, 573-586.	1.9	34
264	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Research and Treatment, 2010, 123, 387-396.	1.1	39
265	Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells. Breast Cancer Research and Treatment, 2010, 124, 121-131.	1.1	23
266	Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?. Progress in Cardiovascular Diseases, 2010, 53, 105-113.	1.6	234
267	Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. , 2010, 125, 196-218.		126
268	Early response to ErbB2 overexpression in polarized Caco2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling. Journal of Cellular Biochemistry, 2010, 111, 643-652.	1.2	5
269	Synthesis and biodistribution studies of ^{177}Lu -trastuzumab as a therapeutic agent in the breast cancer mice model. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 575-579.	0.5	13
270	Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology, 2010, 56, 560-572.	1.6	63
271	Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. British Journal of Cancer, 2010, 102, 513-519.	2.9	29
272	Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. British Journal of Cancer, 2010, 102, 520-529.	2.9	29

#	ARTICLE	IF	CITATIONS
273	Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2010, 103, 1331-1334.	2.9	10
274	CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1496-1512.	3.0	148
275	Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 75-87.	1.5	18
276	HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. <i>PLoS Biology</i> , 2010, 8, e1000563.	2.6	116
277	Cardiotoxicity. <i>Annals of Oncology</i> , 2010, 21, vii173-vii179.	0.6	61
278	Mitral Regurgitation due to Papillary Muscle Dyssynchrony during Trastuzumab Treatment. <i>Cardiology</i> , 2010, 117, 296-300.	0.6	12
279	The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 461-478.	2.4	74
280	HER2 as a target for breast cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 711-724.	1.4	78
281	Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. <i>Journal of Hepatology</i> , 2010, 53, 677-685.	1.8	49
282	Folate-Immunoglobulin G as an Anticancer Therapeutic Antibody. <i>Bioconjugate Chemistry</i> , 2010, 21, 961-968.	1.8	17
283	Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, S41-S50.	1.9	28
284	Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. <i>Breast Cancer Research</i> , 2010, 12, R62.	2.2	45
285	Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1433-1445.	1.4	15
286	Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. <i>British Journal of Cancer</i> , 2011, 105, 796-806.	2.9	125
287	Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. <i>Breast Cancer Research</i> , 2011, 13, R54.	2.2	64
288	Novel method for differentiation between Trastuzumab and host adaptive response. <i>Molecular Immunology</i> , 2011, 48, 1882-1885.	1.0	0
289	Characterization of Novel Murine Monoclonal Antibodies Directed Against the Extracellular Domain of Human HER2 Tyrosine Kinase Receptor. <i>Hybridoma</i> , 2011, 30, 347-353.	0.5	27
290	Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition. <i>Journal of Immunology</i> , 2011, 187, 3383-3390.	0.4	41

#	ARTICLE	IF	CITATIONS
291	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 347-356.	1.1	433
292	Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 67-76.	1.4	23
293	Site-specific modification of ED-B-targeting antibody using intein-fusion technology. <i>BMC Biotechnology</i> , 2011, 11, 76.	1.7	30
294	T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. <i>International Journal of Cancer</i> , 2011, 128, 390-401.	2.3	53
295	ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. <i>Modern Pathology</i> , 2011, 24, 1055-1059.	2.9	9
296	Preclinical development of molecular-targeted agents for cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 200-209.	12.5	145
297	IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN- γ Production. <i>Journal of Immunology</i> , 2011, 186, 3401-3409.	0.4	95
298	Stimulated γ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer. <i>Journal of Immunology</i> , 2011, 187, 1031-1038.	0.4	99
299	Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. <i>Breast Disease</i> , 2011, 32, 35-48.	0.4	518
300	Bi-specific Aptamers Mediating Tumor Cell Lysis. <i>Journal of Biological Chemistry</i> , 2011, 286, 21896-21905.	1.6	124
301	IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance. <i>Journal of Biological Chemistry</i> , 2011, 286, 29734-29747.	1.6	37
302	Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment. <i>Clinical Cancer Research</i> , 2011, 17, 1509-1520.	3.2	34
303	Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics. <i>International Journal of Molecular Sciences</i> , 2012, 13, 12268-12286.	1.8	40
304	Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. <i>Oncolmmunology</i> , 2012, 1, 810-821.	2.1	55
305	Structure Based Antibody-Like Peptidomimetics. <i>Pharmaceuticals</i> , 2012, 5, 209-235.	1.7	21
306	Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1467-1476.	1.9	54
307	CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma. <i>Clinical Cancer Research</i> , 2012, 18, 5352-5363.	3.2	78
308	Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues regarding Dual HER2-Targeted Therapy. <i>Breast Cancer: Basic and Clinical Research</i> , 2012, 6, BCBCR.S9301.	0.6	10

#	ARTICLE	IF	CITATIONS
309	Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. <i>ISRN Oncology</i> , 2012, 2012, 1-16.	2.1	68
310	Targeting the HER2 Receptor in Metastatic Breast Cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2012, 5, 127-137.	0.6	29
311	Therapeutic Antibodies Against Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 447-481.	0.9	71
312	Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. <i>Breast Cancer Research</i> , 2012, 14, R93.	2.2	50
313	Detection of trastuzumab efficacy using 1H MRI ex vivo of breast cancer cells. <i>Medicinal Chemistry Research</i> , 2012, 21, 2316-2319.	1.1	4
314	Maximizing tumour exposure to anti- α -neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. <i>British Journal of Pharmacology</i> , 2012, 166, 368-377.	2.7	39
315	Novel targeted agents for gastric cancer. <i>Journal of Hematology and Oncology</i> , 2012, 5, 31.	6.9	43
317	Potential Therapeutic Significance of HER-Family in Esophageal Squamous Cell Carcinoma. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2012, 18, 506-513.	0.3	14
318	Influence of Alternative Tubulin Inhibitors on the Potency of Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate. <i>Cancer and Clinical Oncology</i> , 2012, 1, 49-80.	0.2	4
319	New developments in the treatment of HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 53.	1.0	10
320	Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. <i>Annals of Oncology</i> , 2012, 23, 1788-1795.	0.6	112
321	Impact of expression system on the function of the C6.5 diabody PET radiotracer. <i>Tumor Biology</i> , 2012, 33, 617-627.	0.8	6
322	ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. <i>Medicinal Research Reviews</i> , 2012, 32, 166-215.	5.0	72
323	Dual HER2-targeted approaches in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 371-383.	1.1	57
324	Targeting HER2 + breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. <i>Journal of Controlled Release</i> , 2013, 172, 395-404.	4.8	47
325	Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. <i>Advances in Therapy</i> , 2013, 30, 645-658.	1.3	21
326	Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2. <i>Structure</i> , 2013, 21, 1979-1991.	1.6	111
327	Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. <i>Gastric Cancer</i> , 2013, 16, 571-580.	2.7	18

#	ARTICLE	IF	CITATIONS
328	Design and evaluation of radiolabeled tracers for tumor imaging. <i>Biotechnology and Applied Biochemistry</i> , 2013, 60, 365-383.	1.4	15
329	Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. <i>Cancer Discovery</i> , 2013, 3, 224-237.	7.7	697
330	Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 395-409.	0.2	62
331	Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2013, 32, 395-409.	0.2	30
332	Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability. <i>Toxicology and Applied Pharmacology</i> , 2013, 273, 298-313.	1.3	162
333	The evolving landscape of protein kinases in breast cancer: Clinical implications. <i>Cancer Treatment Reviews</i> , 2013, 39, 68-76.	3.4	20
334	HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 266-273.	3.0	168
335	The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines. <i>Oncology Reports</i> , 2013, 29, 1268-1274.	1.2	7
336	HER-2 as a Prognostic and Predictive Biomarker in Cancer. , 2013, , 77-120.		0
337	Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 89.	1.0	17
338	Monocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2014, 4, 18.	1.8	11
339	Paclitaxel Enhances Antibody-dependent Cell-mediated Cytotoxicity of Trastuzumab by Rapid Recruitment of Natural Killer Cells in HER2-positive Breast Cancer. <i>Journal of Nippon Medical School</i> , 2014, 81, 211-220.	0.3	18
340	Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 163-170.	1.1	37
341	Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines. <i>Cancer Cell International</i> , 2014, 14, 10.	1.8	18
342	Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer. , 2014, , 239-255.		11
343	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, e58-e68.	5.1	244
344	Trastuzumab emtansine: mechanisms of action and drug resistance. <i>Breast Cancer Research</i> , 2014, 16, 209.	2.2	407
345	A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. <i>AAPS Journal</i> , 2014, 16, 994-1008.	2.2	72

#	ARTICLE	IF	CITATIONS
346	Functions of Antibodies. <i>Microbiology Spectrum</i> , 2014, 2, AID-0019-2014.	1.2	139
347	Comparison of intratumoral heterogeneity of <sc>HER2</sc> expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case. <i>Pathology International</i> , 2015, 65, 309-317.	0.6	6
348	Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s2, BCBCR.S29371.	0.6	5
349	NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 368.	2.2	411
350	Gastric Cancer: New Drugs - New Strategies. <i>Gastrointestinal Tumors</i> , 2015, 1, 180-194.	0.3	15
351	Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 597-605.	1.1	24
352	Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 711-719.	2.7	25
353	HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. <i>Cancer Discovery</i> , 2015, 5, 832-841.	7.7	250
354	Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation. , 2015, , 391-491.		5
355	Molecular Mechanisms in Gastric Carcinogenesis. , 2015, , 35-56.		1
356	General Aspects of Cancer Chemotherapy. , 2015, , 1-22.		5
357	Anticancer activity of galactoxyloglucan polysaccharide-conjugated doxorubicin nanoparticles: Mechanistic insights and interactome analysis. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 183-195.	2.0	21
358	Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2. <i>Cancer Cell</i> , 2015, 27, 489-501.	7.7	158
359	Head and Neck Tumors. , 2015, , 303-339.		0
360	Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment. , 2015, , 341-361.		0
361	Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). <i>Journal of Nutritional Biochemistry</i> , 2015, 26, 16-23.	1.9	27
362	Metformin Effects on Malignant Cells and Healthy PBMC; The Influence of Metformin on the Phenotype of Breast Cancer Cells. <i>Pathology and Oncology Research</i> , 2015, 21, 605-612.	0.9	4
363	Dexamethasone-(C₂₁-phosphoramidate)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2575-2597.	2.0	2

#	ARTICLE	IF	CITATIONS
364	Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine. <i>PLoS ONE</i> , 2016, 11, e0157114.	1.1	4
365	Optimal Synthetic Glycosylation of a Therapeutic Antibody. <i>Angewandte Chemie</i> , 2016, 128, 2407-2413.	1.6	21
366	A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 755-760.	1.0	4
367	Optimal Synthetic Glycosylation of a Therapeutic Antibody. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 2361-2367.	7.2	122
369	Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine. <i>Chinese Journal of Integrative Medicine</i> , 2016, 22, 243-250.	0.7	5
370	Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action. <i>Analytical Chemistry</i> , 2016, 88, 10259-10265.	3.2	20
371	Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. <i>Oncolmmunology</i> , 2016, 5, e1199311.	2.1	21
372	Interaction of a standardized mistletoe (<i>Viscum album</i>) preparation with antitumor effects of Trastuzumab in vitro. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 271.	3.7	30
373	Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B. <i>Clinical and Translational Medicine</i> , 2016, 5, 32.	1.7	2
374	Population pharmacokinetic and exposureâ€“response analysis for trastuzumab administered using a subcutaneous â€œmanual syringeâ€•injection or intravenously in women with HER2-positive early breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 77-88.	1.1	52
375	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. <i>Tumor Biology</i> , 2016, 37, 127-140.	0.8	9
376	Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. <i>Future Oncology</i> , 2016, 12, 1413-1428.	1.1	24
377	Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2017, 28, 1102-1114.	1.8	35
378	Breast Cancer Cardio-Oncology. , 2017, , 241-252.		0
379	PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression. <i>European Journal of Cell Biology</i> , 2017, 96, 469-475.	1.6	14
380	Perspectives of HER2-targeting in gastric and esophageal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 531-540.	1.9	71
381	Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, e172085.	3.4	37
382	Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types. <i>MBio</i> , 2017, 8, .	1.8	33

#	ARTICLE	IF	CITATIONS
383	Gemcitabine-5-phosphoramidate [anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549). <i>Chemical Biology and Drug Design</i> , 2017, 89, 379-399.	1.5	4
384	Trastuzumab cardiotoxicity: from clinical trials to experimental studies. <i>British Journal of Pharmacology</i> , 2017, 174, 3727-3748.	2.7	95
385	Progesterone impairs Herceptin effect on breast cancer cells. <i>Oncology Letters</i> , 2017, 15, 1817-1822.	0.8	1
386	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , 2017, 8, 73144-73153.	0.8	24
387	Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. <i>Cancer Science</i> , 2018, 109, 1166-1176.	1.7	29
388	Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. <i>Journal of Immunology</i> , 2018, 200, 3485-3494.	0.4	22
389	Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. <i>Molecular Oncology</i> , 2018, 12, 441-462.	2.1	15
390	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. <i>Oncotarget</i> , 2018, 9, 31915-31919.	0.8	14
391	Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 647-654.	0.7	12
392	Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil. <i>Journal of Translational Medicine</i> , 2018, 16, 120.	1.8	17
393	Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 8043-8054.	0.9	1
394	Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 379-390.	1.0	5
395	EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. <i>International Journal of Cancer</i> , 2019, 145, 2440-2449.	2.3	20
396	Mechanism of action of the trastuzumab biosimilar CT-P6. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1085-1095.	1.4	11
397	Anti-neoplastic cytotoxicity by complementary simultaneous selective targeted delivery for pulmonary adenocarcinoma: fludarabine-5-phosphoramidate-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]. <i>Journal of Pharmaceutical Investigation</i> , 2019, 49, 173-193.	2.7	5
398	Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 641-654.	1.1	4
399	A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2020, 21, 73.	1.3	1
400	Pharmacotherapeutics of capecitabine and trastuzumab in the treatment of metastatic breast cancer. <i>British Journal of Nursing</i> , 2020, 29, S4-S9.	0.3	3

#	ARTICLE	IF	CITATIONS
401	The Current Landscape of Antibody-based Therapies in Solid Malignancies. <i>Theranostics</i> , 2021, 11, 1493-1512.	4.6	20
402	Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer. <i>DNA and Cell Biology</i> , 2021, 40, 405-413.	0.9	5
403	Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells. <i>ACS Chemical Biology</i> , 2021, 16, 414-428.	1.6	16
404	Immunotherapy as a partner for HER2-directed therapies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 739-746.	1.1	5
405	Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature. <i>Oncologist</i> , 2021, 26, 640-646.	1.9	6
406	The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models. <i>Cancers</i> , 2021, 13, 2778.	1.7	3
407	Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells. <i>Pharmaceuticals</i> , 2021, 14, 624.	1.7	6
408	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 177-185.	1.1	15
409	Therapy-Induced Apoptosis in Primary Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2007, 608, 31-51.	0.8	9
411	Non-fucosylated Therapeutic Antibodies: The Next Generation of Therapeutic Antibodies. , 2008, , 1-9.		1
412	Polyclonal and Monoclonal Antibodies in Clinic. <i>Methods in Molecular Biology</i> , 2014, 1060, 79-110.	0.4	30
414	Monoclonal antibody therapy. , 2009, , 303-406.		4
415	Monoclonal antibody therapy. , 2003, , 329-390.		3
416	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
417	Monoclonal antibody therapy for breast cancer: Herceptin. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 223-233.	0.5	36
418	Anthracyclines. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, , 19-33.	0.5	2
419	Functions of Antibodies. , 0, , 23-48.		58
420	IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. <i>Journal of Clinical Investigation</i> , 2002, 110, 983-992.	3.9	142

#	ARTICLE	IF	CITATIONS
421	IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. <i>Journal of Clinical Investigation</i> , 2002, 110, 983-992.	3.9	114
422	Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. <i>Journal of Clinical Investigation</i> , 2004, 113, 709-717.	3.9	64
423	Hunk is required for HER2/neu-induced mammary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2011, 121, 866-879.	3.9	30
424	Cytotoxic Therapy and Other Nonhormonal Approaches for the Treatment of Metastatic Breast Cancer. , 2002, , 417-472.		1
425	Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis. <i>PLoS ONE</i> , 2011, 6, e23270.	1.1	8
426	Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. <i>PLoS ONE</i> , 2012, 7, e45127.	1.1	15
427	Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription. <i>PLoS ONE</i> , 2013, 8, e62304.	1.1	30
428	Substitution of Heavy Complementarity Determining Region 3 (CDR-H3) Residues Can Synergistically Enhance Functional Activity of Antibody and Its Binding Affinity to HER2 Antigen. <i>Molecules and Cells</i> , 2016, 39, 217-228.	1.0	5
429	FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?. <i>World Journal of Oncology</i> , 2015, 6, 437-440.	0.6	5
430	First-in-human phase 0 study of ¹¹¹ In-CHX-A''-DTPA trastuzumab for HER2 tumor imaging. <i>Journal of Translational Science</i> , 2018, 5, .	0.2	11
431	Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. <i>Journal of Cancer Research and Therapeutic Oncology</i> , 2013, 2, .	0.0	2
432	Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. <i>Oncotarget</i> , 2013, 4, 1592-1605.	0.8	132
433	Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies. <i>Oncotarget</i> , 2020, 11, 3531-3557.	0.8	13
434	Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab. <i>Oncotarget</i> , 2016, 7, 13013-13030.	0.8	7
435	Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. <i>Oncotarget</i> , 2016, 7, 18424-18439.	0.8	45
436	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. <i>Oncotarget</i> , 2016, 7, 50643-50655.	0.8	10
437	Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549). <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 802-819.	0.9	7
438	Emerging therapies in gastrointestinal cancers. <i>World Journal of Gastroenterology</i> , 2006, 12, 7440.	1.4	24

#	ARTICLE	IF	CITATIONS
439	Clinical management of advanced gastric cancer: The role of new molecular drugs. World Journal of Gastroenterology, 2014, 20, 14537.	1.4	41
440	The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. Journal of Carcinogenesis, 2014, 13, 13.	2.5	4
441	Fludarabine- (C2-methylhydroxyphosphoramidate)- [anti-IGF-1R]: Synthesis and Selectively Targeted Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549). Journal of Pharmaceutics & Drug Delivery Research, 2015, 04, .	0.0	4
442	Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium. Journal of Cancer Therapy, 2011, 02, 22-39.	0.1	14
443	Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine. Journal of Cancer Therapy, 2015, 06, 62-89.	0.1	2
444	Signal Transduction and Apoptosis. , 2001, , 253-270.		0
445	Die Herceptintherapie ist keine Wunderwaffe gegen Brustkrebs. , 2002, , 269-273.		0
446	Antineoplastische Therapie. , 2003, , 553-632.		0
447	Treatment with Monoclonal Antibodies. , 2004, , 529-568.		0
449	Exploring Membrane Microdomains and Functional Protein Clustering in Live Cells with Flow and Image Cytometric Methods. , 2004, , 99-120.		1
450	Monoclonal and Bispecific Antibodies in Combination with Radiotherapy for Cancer Treatment. , 2004, , 119-139.		0
452	Immunotherapy of Cancer. , 2009, , 209-240.		1
453	PEG- Anticancer Drugs. , 2010, , 221-263.		0
454	Synthesis of Gemcitabine-(C₄-amide)-[anti-HER2/neu]- Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. Journal of Cancer Therapy, 2012, 03, 689-711.	0.1	9
455	Indications et gestion des effets secondaires. , 2013, , 243-257.		0
456	Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3). , 2013, 03, 210-223.		1
457	Pharmacology and Clinical Development of New Molecularly Targeted Agents. Current Clinical Pathology, 2015, , 9-29.	0.0	0
458	Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. , 2017, , 1-31.		0

#	ARTICLE	IF	CITATIONS
459	Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 191-221.	0.1	2
460	Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast. , 2019, , 237-268.		0
461	Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 3514-3520.	0.1	1
462	Treatment of early stage (T1) esophageal adenocarcinoma: Personalizing the best therapy choice. World Journal of Meta-analysis, 2019, 7, 406-417.	0.1	0
463	miRâ€‘135bâ€‘5p enhances the sensitivity of HERâ€‘2 positive breast cancer to trastuzumab via binding to cyclinâ€‘D2. International Journal of Molecular Medicine, 2020, 46, 1514-1524.	1.8	5
465	Tumor models for preclinical development of targeted agents. , 2005, 63, 43-66.		1
466	Herceptin Resistance. , 2006, , 459-467.		0
468	Tiermodelle in der biomedizinischen Forschung. , 2008, , 207-241.		0
470	Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Design, Development and Therapy, 2009, 3, 7-16.	2.0	77
471	The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. Experimental and Clinical Cardiology, 2009, 14, e62-7.	1.3	8
472	Lapatinib: the evidence for its therapeutic value in metastatic breast cancer. Core Evidence, 2005, 1, 77-87.	4.7	1
473	Functions of Antibodies. Microbiology Spectrum, 2014, 2, 1-17.	1.2	50
475	Gemcitabine-(C)-[anti-HER2/] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. Journal of Clinical & Experimental Oncology, 2013, 2, .	0.1	8
476	Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. American Journal of Cancer Research, 2016, 6, 2661-2678.	1.4	13
477	Cytotoxicity effect of trastuzumab on canine peripheral blood mononuclear cells. Iranian Journal of Veterinary Research, 2020, 21, 263-268.	0.4	0
478	Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication. American Journal of Cancer Research, 2021, 11, 3935-3945.	1.4	0
479	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. , 2022, 236, 108108.		25
480	MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines. Cells, 2022, 11, 117.	1.8	5

#	ARTICLE	IF	CITATIONS
481	Cancer Pharmacogenomics. , 2005, , 339-357.		0
482	Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. Molecular Cancer Therapeutics, 2004, 3, 1335-1342.	1.9	81
483	Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo. Scientific Reports, 2022, 12, .	1.6	2
484	Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line. Cancer Research, 2005, 65, 473-482.	0.4	378
485	Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase. Cancer Research, 2005, 65, 650-656.	0.4	70
487	Research Progress of Targeted Combined Immunization in HER2 Positive Advanced Gastric Cancer: From Bench to Bedside. Advances in Clinical Medicine, 2023, 13, 5864-5871.	0.0	0